Table of Contents Author Guidelines Submit a Manuscript
Volume 2, Pages 791-800
Mini-Review Article

Pharmacogenetics of Antiplatelet Drugs

Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, 123 St. Stephen’s Green, Dublin 2, Ireland

Received 7 December 2001; Revised 1 February 2002; Accepted 21 March 2002

Copyright © 2002 Ronan Curtin and Desmond J. Fitzgerald.


Pharmacogenetics refers to the genetic factors that influence the response to a drug, often involving genetic variations in drug metabolizing enzymes. The pharmacogenetics of antiplatelet agents is in its infancy and largely reflects variations in drug targets or related genes. One particular gene variant, the PlA2 polymorphism of the glycoprotein (GP) IIb/IIIa receptor, is now emerging as a probable determinant of the response to antiplatelet agents including GPIIb/IIIa antagonists. This variant may in part explain the heterogeneity in the response to GPIIb/IIIa antagonists. The PlA2 genotype appears to be associated with an adverse outcome in patients treated with an oral GPIIb/IIIa antagonist and may be a factor in the observed failure of these agents in unselected populations. However, there are preliminary indications that other antiplatelet agents may have an enhanced effect in PlA2 subjects. Further clinical trials in particular are required to definitively characterize the pharmacogenetic effect of PlA2. Other polymorphisms are also likely to contribute to the pharmacogenetics of antiplatelet agents, but these await investigation.